AstraZeneca modifies the effectiveness of its vaccine after global pressure

Follow-up

AstraZeneca said Thursday that its COVID-19 vaccine has reached 76 percent effectiveness in a new analysis of its flagship trial in the United States.
And US health officials this week publicly blamed the drug company for using "outdated information" when it estimated the vaccine was 79 percent effective.
The latest data was based on 190 infections among more than 32,400 participants in the US, Chile and Peru trial.
The previous initial data were 141 injuries as of February 17
"The basic analysis is consistent with our initial analysis previously issued, and confirms that our COVID-19 vaccine is highly effective in adults," said Main Pangalos, executive vice president of biomedical research and development at AstraZeneca.
AstraZeneca said that it "intends to seek approval from the United States for the emergency use of its drug in the coming weeks, and that it has submitted the latest data to the Data Safety Watch, the independent committee to oversee the experiment."
Today, AstraZeneca confirmed that
"The vaccine that I developed with the University of Oxford is 100 percent effective against severe or critical forms of the disease."
Added to that the effectiveness of the vaccine is 85 percent among adults over the age of 65.